recursion pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. our platform has resulted in the massive parallelization of drug discovery. we have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. we partner or out-license these leads to major pharmaceutical companies early in development. our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.
Company profile
Ticker
RXRX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Recursion Pharmaceuticals, LLC
SEC CIK
Corporate docs
Subsidiaries
Recursion Pharmaceuticals Canada, Inc. • Valence Discovery Inc. • Valence Discovery USA, Inc. • Cyclica Therapeutics Inc. • Cyclica Ltd. • Cyclica Inc. • Giro Health Inc. • 1414517 B.C. Unlimited Liability Company • CereXis, Inc. ...
IRS number
464099738
RXRX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
8-K
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
16 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
27 Feb 24
8-K
Departure of Directors or Certain Officers
7 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
31 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Regulation FD Disclosure
20 Dec 23
Latest ownership filings
4
Blake Borgeson
18 Apr 24
4
Michael Secora
18 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
144/A
Notice of proposed sale of securities (amended)
16 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
4
Christopher Gibson
5 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Dean Y Li
3 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 397.21 mm | 397.21 mm | 397.21 mm | 397.21 mm | 397.21 mm | 397.21 mm |
Cash burn (monthly) | 6.54 mm | 5.64 mm | 33.18 mm | 26.01 mm | 24.31 mm | 21.54 mm |
Cash used (since last report) | 44.70 mm | 38.55 mm | 226.82 mm | 177.78 mm | 166.14 mm | 147.22 mm |
Cash remaining | 352.51 mm | 358.65 mm | 170.39 mm | 219.43 mm | 231.06 mm | 249.99 mm |
Runway (months of cash) | 53.9 | 63.6 | 5.1 | 8.4 | 9.5 | 11.6 |
Institutional ownership, Q3 2023
75.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 192 |
Opened positions | 55 |
Closed positions | 22 |
Increased positions | 73 |
Reduced positions | 38 |
13F shares | Current |
---|---|
Total value | 1.13 tn |
Total shares | 171.95 mm |
Total puts | 478.20 k |
Total calls | 422.90 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Baillie Gifford & Co | 24.55 mm | $187.82 bn |
Vanguard | 15.51 mm | $118.63 bn |
BLK Blackrock | 11.86 mm | $90.71 bn |
STT State Street | 11.76 mm | $89.94 bn |
Mubadala Investment Co PJSC | 11.29 mm | $119.58 mm |
FMR | 10.69 mm | $81.77 bn |
Kinnevik AB (publ) | 10.41 mm | $79.60 bn |
MIC Capital Management UK | 8.45 mm | $64.66 bn |
ARK Investment Management | 6.88 mm | $52.61 bn |
Lux Capital Management | 6.00 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Apr 24 | Michael Secora | Class A Common Stock | Sell | Dispose S | No | Yes | 7.583 | 23,124 | 175.35 k | 1,231,055 |
17 Apr 24 | Michael Secora | Class A Common Stock | Option exercise | Acquire M | No | Yes | 2.22 | 37,500 | 83.25 k | 1,254,179 |
17 Apr 24 | Michael Secora | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 2.22 | 37,500 | 83.25 k | 810,135 |
16 Apr 24 | Blake Borgeson | Class A Common Stock | Sell | Dispose S | No | Yes | 7.6636 | 11,447 | 87.73 k | 7,229,861 |
16 Apr 24 | Michael Secora | Class A Common Stock | Sell | Dispose S | No | Yes | 7.6663 | 25,000 | 191.66 k | 1,216,679 |
16 Apr 24 | Michael Secora | Class A Common Stock | Option exercise | Acquire M | No | Yes | 2.22 | 37,500 | 83.25 k | 1,241,679 |
16 Apr 24 | Michael Secora | Stock Option Class A Common Stock | Option exercise | Dispose M | No | No | 2.22 | 37,500 | 83.25 k | 847,635 |
4 Apr 24 | Christopher Gibson | Class A Common Stock | Sell | Dispose S | Yes | Yes | 9.02 | 25,000 | 225.50 k | 0 |
4 Apr 24 | Christopher Gibson | Class A Common Stock | Conversion | Acquire C | Yes | No | 0 | 25,000 | 0.00 | 25,000 |
4 Apr 24 | Christopher Gibson | Class A Common Stock | Sell | Dispose S | No | Yes | 9.02 | 40,000 | 360.80 k | 938,524 |
News
Jim Cramer Says This Energy Stock Is 'Terrific,' Calls Casey's General Stores A 'Winner'
24 Apr 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
24 Apr 24
Cathie Wood's Ark Invest Sells $20M+ Coinbase Shares As Bitcoin Trades Over $70K, Buys Palantir, Sells Nvidia Stock
11 Apr 24
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals
9 Apr 24
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
9 Apr 24
Press releases
Recursion to Participate in Upcoming Investor Conference
2 Apr 24
Thinking about buying stock in BigBear.ai, MicroCloud Hologram, TRACON Pharmaceuticals, Spruce Biosciences, or Recursion Pharmaceuticals?
14 Mar 24
Thinking about buying stock in Recursion Pharmaceuticals, SoundHound AI, Cardiff Oncology, Mind Medicine, or Auddia?
11 Mar 24
Recursion Announces Plans to Open New Office in London
11 Mar 24
Recursion Hosts Second Annual Rare Disease Day Events for Utah's Rare Disease Community
1 Mar 24